FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Top Story

Novartis, Incyte strike potential $1B deal

Wilmington, DE-based Incyte announced today that it will get a hefty $150 million up front and a $60 million milestone payment on a new licensing deal with Novartis that could be worth more than $1 billion. In one fell swoop, Novartis has added two hematology-oncology drug candidates to its pipeline. Report

Special Report

November's biotech stocks to watch

This month three Canaccord Adams analysts--Adam Cutler, George Farmer and Ritu Baral (bios and photos)--weigh in on five developers that are facing pivotal events. Featured in this issue of On the Radar are Cadence Pharmaceuticals, Micromet, Momenta Pharmaceuticals, Pharmasset, and Protalix BioTherapeutics. Report ⇒

Special Report

The 2009 Biotech Graveyard

Biotech GraveyardIn the spirit of Halloween FierceBiotech brings you the 2009 Biotech Graveyard; a list of 16 unfortunate companies that didn't have the money, expertise or programs to survive the economic crisis. Report ⇒

Profile

Emerging Drug Developer: Flexion Therapeutics

Mike Clayman and Neil Bodick are no strangers to the development process. Together they founded Chorus, Eli Lilly's in-house, early-stage development group, which was charged with finding the shortest path possible to proof-of-concept data. And they've garnered $33 million from a Series A to finance their own start-up development outfit, bringing all the skills they've learned along the way to advance therapies taken off the shelves of Big Pharma's R&D operations. Profile